Welcome to our dedicated page for Kura Oncology SEC filings (Ticker: KURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kura Oncology, Inc. (Nasdaq: KURA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports, financial updates and material agreements. As a biopharmaceutical company focused on precision medicines for cancer, Kura uses these filings to report significant events related to its lead menin inhibitor program, KOMZIFTI (ziftomenib), and its broader pipeline.
Recent Form 8-K filings describe key milestones such as full U.S. Food and Drug Administration approval of KOMZIFTI for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation, clinical data from the pivotal KOMET-001 trial, and the wholesale acquisition cost for a one-month supply of KOMZIFTI. Other 8-Ks outline collaboration and co-promotion agreements with Kyowa Kirin, including terms under which Kura leads development, regulatory and commercial strategy in the United States while Kyowa Kirin leads efforts outside the United States.
Filings also cover financial results releases under Item 2.02, inducement equity plans and amendments, and milestone payments associated with the KOMET-017 Phase 3 registrational trials. These documents provide insight into Kura’s commercialization of KOMZIFTI, its clinical development plans for ziftomenib in newly diagnosed and relapsed or refractory AML, and its farnesyl transferase inhibitor programs.
On Stock Titan, investors can review KURA’s SEC filings alongside AI-powered summaries that highlight the main points of each document. This includes quick views of material events, collaboration structures, and key clinical or regulatory disclosures, helping users navigate detailed 8-Ks and related exhibits without reading every line.
Kura Oncology (KURA) reported Q3 2025 results with collaboration revenue of $20.8 million, driven by its Kyowa Kirin partnership, and a net loss of $74.1 million ($0.85 per share). Operating expenses rose to $100.7 million on higher R&D ($67.9 million) and G&A ($32.8 million).
Liquidity remained strong with $549.7 million in cash, cash equivalents and short-term investments as of September 30, 2025. Contract liabilities tied to deferred collaboration revenue totaled $317.6 million, reflecting services to be delivered; receivables from collaborators were $35.9 million. Shares outstanding were 87.0 million as of October 31, 2025.
The company’s NDA for ziftomenib in relapsed/refractory NPM1-mutated AML was accepted with Priority Review and a PDUFA target action date of November 30, 2025. Kura also amended its term loan on October 25, 2025 to extend interest-only payments, with a further extension possible upon an approval milestone.
Kura Oncology (KURA) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025, along with a corporate update.
The information under Item 2.02 and Exhibit 99.1 is being furnished, not deemed “filed” under Section 18 of the Exchange Act, and will not be incorporated by reference into Securities Act registrations unless specifically identified.
Kura Oncology announced receipt of a $30 million milestone payment from Kyowa Kirin. The payment was triggered by dosing the first patient in KOMET-017, a pair of Phase 3 registrational trials evaluating ziftomenib, a once-daily, investigational oral menin inhibitor.
KOMET-017 consists of two independent, global, randomized double-blind, placebo-controlled Phase 3 studies. They assess ziftomenib in combination with intensive and non‑intensive chemotherapy in adults with newly diagnosed NPM1‑mutated or KMT2A‑rearranged acute myeloid leukemia. The payment provides non-dilutive funding aligned with the advancement of ziftomenib into late‑stage testing.
Kura Oncology amended its 2023 Inducement Option Plan to reserve an additional 750,000 shares of common stock, increasing the plan’s total reserve to 3,250,000 shares. These shares are designated exclusively for nonstatutory stock option grants to new hires as an inducement to join the company, consistent with Nasdaq Listing Rule 5635(c)(4). The Board approved the amendment on October 15, 2025, without stockholder approval as permitted by the rule. A complete copy of the amended plan is filed as Exhibit 99.1.
Kura Oncology (KURA) Form 144 notice states that an individual proposes to sell 8,891 shares of common stock on or about 09/29/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filing reports an aggregate market value of $80,463.55 and total shares outstanding of 87,015,518. The shares were acquired as RSUs from the issuer on 09/27/2025 and are listed as payable on 09/29/2025. The filer reports no sales of the issuer's securities in the past three months and includes the standard signature representation that no undisclosed material adverse information is known.
Kura Oncology (KURA) Form 144 notice reports a proposed sale of 36,615 shares of common stock, to be executed on 09/29/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The shares were acquired as PSUs from the issuer on 09/27/2025 and carry an aggregate market value of $331,365.75 based on the filing. The filing states there were no securities sold by the reporting person in the prior three months.
The notice includes the standard representation that the seller does not possess any undisclosed material adverse information about the issuer and references Rule 10b5-1 plan disclosure as applicable. No other financial results, holdings, or related-party details are provided in the document.
Form 144 notice summary: This filing reports a proposed sale of 4,541 shares of Kura Oncology common stock on NASDAQ through Morgan Stanley Smith Barney LLC on 09/29/2025. The shares were acquired as PSUs from the issuer on 09/27/2025. The filing lists an aggregate market value of $41,096.05 based on reported figures and shows 87,015,518 shares outstanding. The filer reports no securities sold in the past three months and includes the standard attestation regarding absence of undisclosed material information.
Kura Oncology (KURA) filed a Form 144 reporting a proposed sale of 8,805 shares of common stock valued at $79,685.25. The shares were acquired as performance stock units (PSUs) on 09/27/2025 and the proposed sale date is 09/29/2025 through Morgan Stanley Smith Barney LLC on the NASDAQ. The filing shows 87,015,518 shares outstanding, and declares no securities sold by the reporting person in the prior three months. The filer certifies they are unaware of undisclosed material adverse information.
Kura Oncology Form 144 notice reporting a proposed sale of 12,314 shares of common stock. The filer intends to sell the shares through Morgan Stanley Smith Barney LLC on NASDAQ around 09/29/2025, with an aggregate market value listed at $111,441.70. The shares were acquired two days earlier on 09/27/2025 as performance stock units (PSUs) issued by the company and are to be paid/settled on 09/29/2025. The filing states there were no other securities sold by the same person in the past three months and includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.
Kura Oncology (KURA) filed a Form 144 reporting a proposed sale of 6,892 shares of common stock through Morgan Stanley Smith Barney LLC on 09/29/2025. The filing lists the aggregate market value of the shares as $62,372.60 and indicates 87,015,518 shares outstanding. The securities were acquired as PSUs from the issuer on 09/27/2025, with payment noted on 09/29/2025. The filer reported no securities sold in the past three months and certified they are unaware of undisclosed material adverse information. Other filer contact fields in the form are present but contain no substantive names or contact details.